Bupropion SR vs placebo for smoking cessation in health care professionals
Jean-Pierre Zellweger1, Pal Laszio Boelcskei, Laura Carrozzi
1University Medical Policlinic, 10011 Lausanne, Switzerland. zellwegerjp@swissonline.ch
Objective:
To evaluate bupropion SR for smoking cessation in physicians and nurses.
Methods:
This double-blind prospective 26-center, 12-country trial randomized 687 subjects to smoking cessation counselling with bupropion SR or placebo for 7 weeks. The participants were followed for 52 weeks.
Results:
Bupropion SR was superior to placebo (50% vs 40%, P=0.013) on the 4-week primary outcome variable. Due to a high placebo response in this health care population, statistical differences were not maintained after treatment was discontinued.
Conclusions:
Bupropion SR is effective and well tolerated in health care professionals. Relapse prevention measures are needed to attain long-term abstinence.
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
Antidepressant Drugs: MAOIs and Other Agents
Acute Coronary Syndrome IV: Interprofessional Care
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Stress Prevention and Stress Management Techniques IV
The Placebo Effect
